• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1253152 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type( C4 h/ n# o5 U- C$ C) X1 @
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
% y' p8 e: ]8 v" _- e0 b+ Author Affiliations- A9 |; o( A+ m9 [! x. m, x! e
! d  f' r+ V; Z' [
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 1 P5 [( a. K5 Q+ H) U0 c# h
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
6 o4 q! h0 C; Z" h' K  t8 F; B6 ^3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
  C3 W+ ~# b2 n8 R4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
5 j; V  ]$ e4 k5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan + K9 h, v6 @/ H" n# ~- Y$ D- N
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
1 Q# i0 @& N# q1 r( c7Kinki University School of Medicine, Osaka 589-8511, Japan ! J: h& D. E/ u* ?" M0 C5 T
8Izumi Municipal Hospital, Osaka 594-0071, Japan 2 L8 q0 k( m- e/ `2 |
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
( u9 a8 @# u2 d9 aCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
. \9 f& ^& Q6 T) n) `AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
3 v/ c! y9 }+ ]; P
1 l+ e" @9 V6 g
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
& z* n" B: T' g5 I3 \1 Z+ m& H2 }9 j: |) g
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 9 _1 K" a& E4 m! j
7 L2 a2 d0 X: D& Q# Z% Y: l9 V; E
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  # {; f6 l2 \4 y: Q
: f' n: L" W5 q5 G6 q0 \0 A% P$ L: @
Published online on: Thursday, December 1, 2011
$ W/ L: G7 H) T/ w% ]+ _: w9 ]- L4 p. S
Doi: 10.3892/ol.2011.507 , V+ e! e0 |# r; ?% S

2 |3 a+ F& r) D' L9 V' wPages: 405-410
& V  o8 V! O$ D/ E* y* g
( T: J3 v1 m4 z1 e3 \. `Abstract:& G7 }9 u7 |2 k5 a- C6 i% g2 }
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
7 J2 @$ B5 K7 n# }# z$ a 7 ~: ]3 `+ i% p0 y
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
9 J" q4 N$ g6 c+ bF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
3 b/ e# n% ]0 @/ M" D& P2 R+ Author Affiliations( y# u( e4 o. c
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 2 _* u* ?9 ~% o) U/ L
2Department of Thoracic Surgery, Kyoto University, Kyoto
8 A6 V! ~# c6 E3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
( y" E! x: O4 E) D1 ^. p&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 4 L! h( m# w+ M( [; W9 i9 L( [) {) U
Received September 3, 2010. % b  g8 {# y2 G$ v
Revision received November 11, 2010. 9 J* K, ~/ M3 j* s. S  Y
Accepted November 17, 2010.
( R, m4 B; t  AAbstract: N/ u2 E' m# p% @0 @
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
7 h5 y& o% X4 D! P% JPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. + r. \" X9 _. }/ a; y5 ~3 ?3 r
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. 3 y9 Z' W) \8 [! w) l0 F
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. & L5 v) I6 \9 @% W9 ^+ h8 C, w1 A1 \
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
" P' C$ T" `5 n, I) m2 _7 x今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
) E: \" q7 k+ R
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
4 i7 z7 U6 g) V$ Q* }4 b. z4 Phttp://clinicaltrials.gov/ct2/show/NCT01523587
; l- m, Y! n4 v! X* m- k" o0 P2 R" i7 o; U- m
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
. k) y2 F" }1 j7 U& ehttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
& V% O. K3 ^- Y! v: D7 m% s# k/ [4 ~/ J& d& K
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。# i8 V8 W* k& d6 w# {0 ?9 z; w
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 * Y* q+ {4 L% v' k& ?9 N
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。- |# n8 u! P4 F: c1 m" |+ \
至今为止,未出 ...
" d) Y% R6 @4 D) O$ I9 E; W) U
没有副作用是第一追求,效果显著是第二追求。9 F, b/ O& D( N2 L. `- l0 J$ o
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表